FP
PGNX

Foundry Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Foundry Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,600
Closed -$67K – 457
2016
Q3 		$67K Sell
10,600
-7,275
-41% -$44K ﹤0.01% 371
2016
Q2 		$75K Hold
17,875
– – ﹤0.01% 365
2016
Q1 		$78K Buy
+17,875
New +$79.6K 0.01% 266

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Foundry Partners's PGNX Position: Q4 2016 in Review

Foundry Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2016, closing a stake of 10,600 shares — an estimated $67K sold.

Foundry Partners first reported a position in PGNX in Q1 2016 and held it in 3 quarters. The position peaked at $78K in Q1 2016. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • Foundry Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Foundry Partners sold 10,600 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $67K.
  • Foundry Partners first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 3 quarters.
  • Foundry Partners's Progenics Pharmaceuticals Inc position peaked at $78K in Q1 2016.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on Foundry Partners's 13F filing for Q4 2016, filed 10 Feb 2017.